呂學儒主治醫師
| 現職 | 中山醫學大學附設醫院 血液腫瘤科主任 |
| 專長 | 頭頸癌、免疫治療 |
| 執行臨床試驗案件數(近五年) | 3件 |
| 聯繫方式 | 聯繫電話：0919-035864 聯繫信箱：hsuehju0311@gmail.com |
| 近五年論文著作 |
| 《2024》 ● Lu HJ, Hsieh MC, Wang HM, Hsieh JC, Yen CJ, Wu SY, Huang HC, Wang HC, Chu PY, Chen TH, Chien CY, Huang TL, Chang YF, Hua CH, Lien MY, Chen JP, Lu WC, Lin JC, Wang CC, Liu YC, Yang MH, Lou PJ Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database. Head Neck. 2024 Feb 22. doi: 10.1002/hed.27681. ● Wang HM, Lou PJ, Yang MH, Chen TH, Lien MY, Lin JC, Chen JP, Lu WC, Lu HJ, Huang TL, Yen CJ, Wu SY, Wang HC, Hsieh MC. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08). Target Oncol. 2024 Jan;19(1):51-58. doi: 10.1007/s11523-023-01028-7. ● Lin CW, Yang WE, Su CW, Lu HJ, Su SC, Yang SF. IGF2BP2 promotes cell invasion and epithelial-mesenchymal transition through Src-mediated upregulation of EREG in oral cancer. Int J Biol Sci. 2024 Jan 1;20(3):818-830 ● Lu HJ, Shen CY, Chiu YW, Lin WL, Peng CY, Tseng HC, Hsin CH, Chuang CY, Chen CC, Wu MF, Huang WS, Shen WC. Radiomic biomarkers for platinum-refractory head and neck cancer in the era of immunotherapy. Oral Dis. 2024 Jan 4. doi: 10.1111/odi.14854. 《2023》 ● Chen PJ, Lin CW, Lu HJ, Chuang CY, Yang SF, Chou YE. The impact of FOXP3 polymorphisms on oral cancer progression and clinicopathological characteristics. J Cancer. 2023 May 5;14(7):1195-1201. ●Cheng KL, Lu HJ, Lin X, Wang HY, Chou YH, Tyan YS, Tsai PH. Interval changes of histogram-derived diffusion indices predict treatment response to induction chemotherapy in head and neck cancer: a feasibility study. Quant Imaging Med Surg. 2022 Dec;12(12):5383-5393. 《2022》 ●Lu HJ, Chuang CY, Su CW, Chen MK, Yang WE, Yeh CM, Tang CH, Lin CW, Yang SF. Role of TNFSF15 variants in oral cancer development and clinicopathologic characteristics. J Cell Mol Med. 2022 Nov;26(21):5452-5462 ●Lin SH, Lin CW, Lu JW, Yang WE, Lin YM, Lu HJ (co-corresponder), Yang SF. Cytoplasmic IGF2BP2 Protein Expression in Human Patients with Oral Squamous Cell Carcinoma: Prognostic and Clinical Implications. Int J Med Sci. 2022 Jul 4;19(7):1198-1204 ●Chen PJ, Lu HJ, Nassef Y, Lin CW, Chuang CY, Lee CY, Chiu YW, Yang SF, Yang WE. Association of dipeptidyl peptidase IV polymorphism with clinicopathological characters of oral cancer. J Oral Pathol Med. 2022 Sep;51(8):730-737. ●Lu HJ, Peng CY, Tseng HC, Hsin CH, Chuang CY, Chen CC, Huang WS, Chiu YW, Yang SF. Preoperative prediction model to evaluate salvage surgery in patients with recurrent or second primary oral cavity squamous cell carcinoma. Oral Oncol. 2022 Aug:131:105951. ●Lu HJ, Chuang CY, Chen MK, Su CW, Yang WE, Yeh CM, Lai KM, Tang CH, Lin CW, Yang SF. The impact of ALDH7A1 variants in oral cancer development and prognosis. Aging (Albany NY). 2022 May 25;14(10):4556-4571. ●Lu HJ, Li CH, Kang YT, Wu CM, Wu CH, Ko JL, Wu MF. Efficacy of GMI, a fungal immunomodulatory protein, for head and neck cancer patients with chemotherapy-related oral mucositis: An open-labeled prospective single-arm study. Medicine (Baltimore). 2022 Apr 22;101(16):e29185. ●Lu HJ, Chiu YW, Lan WS, Peng CY, Tseng HC, Hsin CH, Chuang CY, Chen CC, Huang WS, Yang SF. Prediction Model of Distant Metastasis in Oral Cavity Squamous Cell Carcinoma With or Without Regional Lymphatic Metastasis. Front Oncol. 2022 Jan 3;11:713815 《2021》 ●Lin CC, Liao WT, Yang TY, Lu HJ, Hsu SL, Wu CC. MicroRNA‑10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells. Oncol Rep. 2021 Aug;46(2):167. Hsieh MH, Lu HJ, Lin CW, Lee CY, Yang SJ, Wu PH, Chen MK, Yang SF. Genetic Variants of lncRNA GAS5 Are Associated with the Clinicopathologic Development of Oral Cancer. J Pers Med. 2021 Apr 26;11(5):348. ●Lu HJ, Tseng SW, Peng CY, Tseng HC, Hsin CH, Chen HL, Huang WS, Wu MF, Yang MH, Chang PM. Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma.Postgrad Med. 2021 Apr;133(3):377-384. ●Chou CH, Chang CY, Lu HJ(co-first author), Hsin MC, Chen MK, Huang HC, Yeh CM, Lin CW, Yang SF. IGF2BP2 Polymorphisms Are Associated with Clinical Characteristics and Development of Oral Cancer. Int J Mol Sci. 2020 Aug 7;21(16):5662. 《2020》 ●Yeh CM, Lin CW, Lu HJ, Chuang CY, Chou CH, Yang SF, Chen MK. Impact of SRY-Box Transcription Factor 11 Gene Polymorphisms on Oral Cancer Risk and Clinicopathologic Characteristics. Int J Mol Sci. 2020 Jun 23;21(12):4468. 《2019》 Lu HJ, Hsieh CC, Yeh CC, Yeh YC, Wu CC, Wang FS, Lai JM, Yang MH, Wang CH, Huang CF, Chang PM. Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy. Sci Rep. 2019 Sep 9;9(1):12913 |